Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Aldosterone synthase inhibitors in cardiovascular and renal diseases
Pawel Namsolleck, T Unger
Nephrology Dialysis Transplantation (2014) Vol. 29, Iss. suppl 1, pp. i62-i68
Open Access | Times Cited: 53

Showing 1-25 of 53 citing articles:

Obesity, kidney dysfunction and hypertension: mechanistic links
John E. Hall, Jussara M. do Carmo, Alexandre A. da Silva, et al.
Nature Reviews Nephrology (2019) Vol. 15, Iss. 6, pp. 367-385
Open Access | Times Cited: 494
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial
Katherine R. Tuttle, Sibylle J. Hauske, María Eugênia Fernandes Canziani, et al.
The Lancet (2023) Vol. 403, Iss. 10424, pp. 379-390
Open Access | Times Cited: 70
Aldosterone Induces Renal Fibrosis and Inflammatory M1-Macrophage Subtype via Mineralocorticoid Receptor in Rats
Beatriz Martín‐Fernández, Alfonso Rubio‐Navarro, Isabel Cortegano, et al.
PLoS ONE (2016) Vol. 11, Iss. 1, pp. e0145946-e0145946
Open Access | Times Cited: 89
Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double‐blind, placebo‐controlled, Phase I trial
Stefan R. Bornstein, Dick de Zeeuw, Hiddo J.L. Heerspink, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 6, pp. 2128-2138
Open Access | Times Cited: 10
Aldosterone Synthase Inhibitor BI 690517: Specificity for Mineralocorticoid Receptor
Andrew Treihaft, Manish A. Parikh, Kaedrea A. Jackson, et al.
Cardiology in Review (2025)
Closed Access | Times Cited: 1
Update on RAAS Modulation for the Treatment of Diabetic Cardiovascular Disease
Stella Bernardi, Andrea Michelli, Giulia Zuolo, et al.
Journal of Diabetes Research (2016) Vol. 2016, pp. 1-17
Open Access | Times Cited: 85
New mineralocorticoid receptor antagonists: update on their use in chronic kidney disease and heart failure
Irene Capelli, Lorenzo Gasperoni, Marco Ruggeri, et al.
Journal of Nephrology (2019) Vol. 33, Iss. 1, pp. 37-48
Closed Access | Times Cited: 63
The involvement of aldosterone on vascular insulin resistance: implications in obesity and type 2 diabetes
Thiago Bruder‐Nascimento, Marcondes A. B. Silva, Rita C. Tostes
Diabetology & Metabolic Syndrome (2014) Vol. 6, Iss. 1
Open Access | Times Cited: 51
Critical insights into the beneficial and protective actions of the kallikrein–kinin system
D. Regoli, Fernand Gobeil
Vascular Pharmacology (2015) Vol. 64, pp. 1-10
Closed Access | Times Cited: 43
Mega clinical trials which have shaped the RAS intervention clinical practice
Rainer Düsing
Therapeutic Advances in Cardiovascular Disease (2016) Vol. 10, Iss. 3, pp. 133-150
Open Access | Times Cited: 43
Third-generation Mineralocorticoid Receptor Antagonists
Elise P. Gómez-Sánchez
Journal of Cardiovascular Pharmacology (2015) Vol. 67, Iss. 1, pp. 26-38
Open Access | Times Cited: 43
Endogenous Cardiotonic Steroids in Kidney Failure: A Review and an Hypothesis
John M. Hamlyn, Paolo Manunta
Advances in Chronic Kidney Disease (2015) Vol. 22, Iss. 3, pp. 232-244
Open Access | Times Cited: 38
Genetic, Molecular and Clinical Determinants for the Involvement of Aldosterone and Its Receptors in Major Depression
Harald Murck, Matthias Büttner, Tilo Kircher, et al.
Nephron Physiology (2014) Vol. 128, Iss. 1-2, pp. 17-25
Open Access | Times Cited: 35
Mineralocorticoid and SGK1-Sensitive Inflammation and Tissue Fibrosis
Ferruh Artunç, Florian Läng
Nephron Physiology (2014) Vol. 128, Iss. 1-2, pp. 35-39
Open Access | Times Cited: 35
Spironolactone ameliorates arterial medial calcification in uremic rats: the role of mineralocorticoid receptor signaling in vascular calcification
Narihito Tatsumoto, Shunsuke Yamada, Masanori Tokumoto, et al.
AJP Renal Physiology (2015) Vol. 309, Iss. 11, pp. F967-F979
Open Access | Times Cited: 35
Phase 1 studies of the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 690517 (vicadrostat), a novel aldosterone synthase inhibitor, in healthy male volunteers
Friedrich Schulze, Jennifer Schaible, Markus Goettel, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Open Access
Continuous flow-through steady state system for in vitro characterization of CYP11B2 inhibitors – impact on enzyme kinetics of steroidogenesis
Dennis Fröbel, Stefanie Hahner, Britta Heinze, et al.
The Journal of Steroid Biochemistry and Molecular Biology (2025), pp. 106736-106736
Open Access
New Therapies for the Management of Chronic Kidney Disease
Andrew Treihaft, Manish A. Parikh, Kaedrea A. Jackson, et al.
Cureus (2025)
Open Access
Aldosterone induces C-reactive protein expression via MR-ROS-MAPK-NF-κB signal pathway in rat vascular smooth muscle cells
Xiaolu Zhang, Juntian Liu, Xiaoming Pang, et al.
Molecular and Cellular Endocrinology (2014) Vol. 395, Iss. 1-2, pp. 61-68
Closed Access | Times Cited: 33
Ginsenoside Rg1 reduces aldosterone-induced autophagy via the AMPK/mTOR pathway in NRK-52E cells
Li Wang, Nan Mao, Ruizhi Tan, et al.
International Journal of Molecular Medicine (2015) Vol. 36, Iss. 2, pp. 518-526
Open Access | Times Cited: 30
An additive effect of eplerenone to ACE inhibitor on slowing the progression of diabetic nephropathy in the db/db mice.
Guangyu Zhou, Ulrika Johansson, Xiao Rong Peng, et al.
PubMed (2016) Vol. 8, Iss. 3, pp. 1339-54
Closed Access | Times Cited: 30
Aldosterone: Renal Action and Physiological Effects
Jermaine G. Johnston, Amanda Welch, Brian Cain, et al.
Comprehensive physiology (2023), pp. 4409-4491
Closed Access | Times Cited: 9
Methods Article for a Study Protocol: Study Design and Baseline Characteristics for Aldosterone Synthase Inhibition in Chronic Kidney Disease
Katherine R. Tuttle, Peter Rossing, Sibylle J. Hauske, et al.
American Journal of Nephrology (2023) Vol. 55, Iss. 2, pp. 262-272
Open Access | Times Cited: 8
Metabolism of Oral Turinabol by Human Steroid Hormone-Synthesizing Cytochrome P450 Enzymes
Lina Schiffer, Simone Brixius‐Anderko, Frank Hannemann, et al.
Drug Metabolism and Disposition (2015) Vol. 44, Iss. 2, pp. 227-237
Open Access | Times Cited: 28
The potential of targeting CYP11B
Rita Bernhardt
Expert Opinion on Therapeutic Targets (2016) Vol. 20, Iss. 8, pp. 923-934
Closed Access | Times Cited: 27
Page 1 - Next Page

Scroll to top